Clever Culture Systems Ltd Overview
Clever Culture Systems is an Adelaide-based micro-cap medical and laboratory technology company that has spent two decades automating microbiology laboratories. Its sole commercial platform, the APAS® Independence (Automated Plate Assessment System), uses imaging, artificial intelligence and machine learning to read, interpret and report microbiology culture plates after incubation. The company says it is the only US FDA-cleared AI technology for automated culture-plate reading. The platform was first built for clinical diagnostics, where adoption disappointed. A strategic reset in late 2023 pivoted the company toward pharmaceutical environmental monitoring (EM), the high-volume reading of settle and contact plates in sterile drug manufacturing. Since then CCS has won AstraZeneca as an anchor "land-and-expand" customer and has broadened its base to eight top-30 global pharma companies. These include AstraZeneca, Pfizer, Bristol Myers Squibb, Novo Nordisk, Boehringer Ingelheim, Thermo Fisher Pharma Services and CSL Behring. The investment case rests on converting single-instrument evaluations into network-wide multi-instrument deployments while managing a thin cash buffer.
Company's own description
The company's standard boilerplate (Q4 FY26 Appendix 4C, 30 July 2026) describes CCS as a provider of intelligent automation solutions to microbiology laboratories, based in Adelaide. It says CCS has developed the APAS® Independence, which uses AI and machine-learning software to automate the imaging, analysis and interpretation of microbiology culture plates. It states that the technology is the only US FDA-cleared AI technology for automated culture-plate reading. It sells the product to pharmaceutical-manufacturing microbiology laboratories for reading environmental-monitoring plates, and to clinical laboratories as an in-vitro diagnostic for infectious diseases. Thermo Fisher Scientific is exclusive distributor to clinical customers in the US and selected European countries.
Independent characterisation
CCS is a single-product, single-segment capital-equipment-plus-software business with a razor/razor-blade-style revenue model:
Instrument sales (one-off): each APAS® Independence is sold outright (or, since FY26, leased). Management sizes the large-pharma opportunity at about A$0.5m in upfront sales per instrument. This is derived from its statement that 100 instruments equal about A$50m upfront (Q4 FY26 4C).
Annual software licences for analysis modules (recurring): AI "analysis modules" (settle plate, 55mm contact plate, clinical urine, MRSA and others) are licensed annually per instrument.
Maintenance and support (recurring): multi-year service contracts. The AstraZeneca contract carried seven years of maintenance and support (August 2024 ASX release).
Validation services (emerging): paid support to help customers validate APAS® into GMP-regulated routine use. A dedicated UK-based lead was hired in June 2026.
Leasing (new in FY26): CSL Behring took a five-year lease in June 2026.
Grants and R&D tax incentives (non-operating but material): e.g., A$0.74m CTCM matched-funding grant income in H1 FY25 and A$1.07m R&D Tax Incentive received in FY26.
Management states that annual recurring revenue (ARR), mainly high-margin software licences, exceeded A$1.3m per year at 30 June 2026 (Q4 FY26 4C). It frames the medium-term economics as about A$50m upfront plus A$10m ARR if its eight large pharma customers deployed 100 instruments. That implies roughly A$100k ARR per installed instrument at maturity (management estimate, not guidance).
Value-chain position
CCS designs the instrument, develops the AI software, and manages manufacturing, global sales and product development from Australia (H1 FY26 Note 10). It does not make culture media (plates). This is strategically relevant because Thermo Fisher, a dominant culture-media supplier, distributes the clinical version partly to pull through its own media sales (Biotech Daily, June 2022).
Customer types and end-markets
| End-market | Use case | Status | Representative customers |
|---|---|---|---|
| Pharmaceutical manufacturing QC (environmental monitoring) | Reading settle plates and contact plates from cleanroom monitoring | Primary growth market since March 2024 | AstraZeneca, Pfizer, BMS, Novo Nordisk, Boehringer Ingelheim, Thermo Fisher Pharma Services (Patheon), CSL Behring, one unnamed top-30 pharma, a US single-site manufacturer |
| Clinical microbiology (IVD) | Urine culture screening, MRSA screening | Legacy market; sales below expectations; Thermo Fisher inventory depleted in FY26 | US hospitals via Thermo Fisher; Labor Dr Wisplinghoff (Germany) |
Strategy
Stated strategy (company themes)
"Land and Expand": win top-30 global pharma customers with single-instrument placements and evaluations (land), then deploy multiple instruments across their global sterile-manufacturing networks (expand). AstraZeneca, with eleven sales to date (Interim FY26), is the template.
FY26 objective: broaden and diversify the customer base beyond AstraZeneca. This was achieved: large pharma customers rose from four to eight (Q4 FY26 4C).
FY27 objective: the "sales expansion phase", converting existing customers into multi-unit deployments. Management sized this at up to 100 instruments (≈A$50m upfront, ≈A$10m ARR) across the eight large pharma customers, plus about 80 instrument opportunities among new qualified customers.
Initiatives in the last 24 months
| Initiative | Date | Detail |
|---|---|---|
| Pharma pivot and settle-plate module | Mar 2024 | Launched; co-developed with AstraZeneca |
| Contact-plate module | Completed 31 Aug 2025 | Enables full EM coverage; rolled out to installed base |
| Name and brand change | Nov 2024 | LBT Innovations becomes Clever Culture Systems (CC5), aligning with the APAS commercial brand |
| Instrument leasing model | FY26 | First lease to CSL Behring (five years) |
| Paid evaluations | FY26 | Non-refundable deposits during six-month evaluations |
| Validation services | June 2026 | UK-based lead hired; new revenue stream |
| APAS Expert User Group | 2,026 | Customer-formed group of six large pharma members, meeting three to four times a year; potential collective voice to regulators |
| APAS Discovery Day | June 2026 | Held at AstraZeneca Macclesfield; customers from ten countries |
| Technology roadmap | Ongoing | Streamlined plate processing, integration with customers' digital ecosystems (e.g., LIMS), and module refinement from real-world data |
| Capital structure clean-up | Nov 2025 | Option conversion raised A$3.2m; SAFA loan repaid |
| Working-capital debt | June 2026 | A$1.6m unsecured, 10% interest, 16m options attached |
Targets and guidance
-
FY26 placement guidance (at least 11, matching FY25) was met (Q4 FY26 4C).
-
FY27: "sales growth expected", but no quantitative revenue or profit guidance.
-
ESG or cost-programme targets: not publicly disclosed.
Products & Services
Current commercial portfolio
| Product / service | Description | Key capabilities | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|---|
| APAS® Independence (instrument) | Benchtop automated plate-reading instrument: loads, images and interprets incubated culture plates | AI/ML image analysis; permanent digital plate image; consistent reads; FDA-cleared (clinical); off-the-shelf validated modules for both EM plate types | Pharma QC labs; clinical microbiology labs | FDA clearance c.2019–20; contact-plate hardware upgrade Aug 2025 | Outright sale (≈A$0.5m per unit implied by management) or five-year lease (from FY26) |
| APAS® Settle Plate Analysis Module (pharma, formerly "APAS PharmaQC") | AI software to detect microbial growth on 90mm settle plates used in cleanroom EM | Co-developed with AstraZeneca; AstraZeneca pilot reported that no plate with growth was missed | Sterile drug manufacturers | Launched March 2024 | Annual licence per instrument |
| APAS® 55mm Contact Plate Analysis Module | AI software plus instrument enhancements for smaller contact plates | Contact plates are about 50% of EM plate volume; CCS says APAS is the only automated instrument with validated modules for both plate types | Sterile drug manufacturers | Validated and completed 31 Aug 2025 | Annual licence; hardware/software upgrade for existing customers |
| Clinical Urine Analysis Module | Screens urine culture plates and triages negatives | FDA-cleared with the instrument | Clinical labs (US via Thermo Fisher; EU) | c.2019–20 | Annual licence |
| MRSA Analysis Module | Screens MRSA chromogenic plates | FDA-cleared 2021; works on Thermo Fisher and BD media | Clinical labs | 2,021 | Annual licence |
| Maintenance and support | Installation, qualification, servicing | Multi-year (e.g., seven years for AstraZeneca) | All customers | Ongoing | Annual or multi-year contracts |
| Validation services | Supports customers through GMP evaluation and validation | Programme to shorten validation time; UK-based lead hired June 2026 | Pharma | Formalised FY26 | Fee for service (pricing not disclosed) |
Legacy and pipeline technologies (historical LBT portfolio)
| Technology | Description | Status |
|---|---|---|
| MicroStreak | Automated culture-plate streaking and inoculation; LBT's first product, commercialised via bioMérieux | Rights returned to LBT; not currently marketed |
| Automated Gram Stain Assessment (AGSA) | AI interpretation of Gram-stain images | — |
| WoundVue | AI-assisted assessment of chronic wounds | — |
| Biofilm detection | Detecting biofilms in the presence of mammalian tissue | — |
| APAS urine/infection-control/AST extensions | Additional clinical applications | Referenced historically; not current priority |
These appear in aggregator profiles of the company but are not featured in recent company disclosures. Their current status (active, shelved or licensed) is not publicly disclosed.
Financial Narrative
FY2026 audited results were not available. FY26 cash-flow data come from the unaudited Q4 FY26 Appendix 4C.
Income statement: notes and sources
Sources: StockAnalysis income statement (aggregator); FY22 Appendix 4E (net loss FY21 A$7.26m, FY22 A$6.64m confirmed); TipRanks/FY25 results (net profit A$1.68m confirmed); Simply Wall St/Yahoo (EPS FY25 A$0.001 vs FY24 A$0.004 loss). FY23 net loss includes the A$13.4m APAS impairment (Interim FY26 Note 1).
Margins
Revenue CAGR FY21–FY25 (ordinary revenue): about 48.6% a year (A$1.12m to A$5.46m). This is computed and flattered by a very low base.
Half-year bridge (most recent audited/reviewed data)
Source: H1 FY26 Interim Report (17 Feb 2026). Management attributes the A$2.3m pre-tax swing to (1) A$0.91m of grants and other income in the prior period that did not recur; (2) A$0.68m of staff costs capitalised on contact-plate development in the prior period, now expensed after the project completed on 31 Aug 2025; and (3) A$0.31m higher non-cash charges (depreciation and share-based payments).
Balance sheet
Sources: H1 FY26 Interim Report (30 Jun 2025 comparatives; 1 July 2024 equity A$2.423m); FY22 Appendix 4E (NTA); H1 FY25 report (NTA 30 Jun 2024).
Post-FY25 balance-sheet trajectory
Sources: H1 FY26 Interim; Q4 FY26 4C. A$1.68m (A$1.6m principal plus A$80k interest) falls due on 31 Dec 2026.
Intangibles detail (31 Dec 2025). The gross carrying amount is A$16.1m before impairment. This comprises A$13.4m of "pre-pharma" APAS development (fully impaired in FY23) and A$2.7m of capitalised contact-plate development. The directors have not reversed the A$13.4m impairment, citing insufficient "reasonable and supportable" evidence until the expand phase is proven. A reversal would be a material positive signal to watch.
Cash flow: notes and sources
Source: FY26 figures from the Q4 FY26 Appendix 4C (12-month year-to-date, unaudited). H1 FY25 operating cash flow was +A$0.30m and H1 FY26 +A$0.19m (Interim reports). The company reported two consecutive quarters of positive operating cash flow in H2 FY25 (TipRanks summary of quarterly).
Commentary on trends and drivers
-
FY21–FY23, the clinical years. Revenue stalled at about A$1–2m a year while the business burned about A$7–8m of operating losses annually. This was consistent with the about A$7.5m annual cash burn cited in 2022 (Stockhead). Clinical labs adopted slowly despite FDA clearance and the Thermo Fisher partnership. The FY23 impairment (A$13.4m) recognised that the clinical business case could not support the capitalised asset base.
-
FY24, the reset. Revenue fell 41% as clinical sales dried up, but the cost base was cut: operating loss narrowed from A$7.1m to A$4.7m. The Nov 2023 recapitalisation and SA loan restructure bought time to finish the AstraZeneca-co-funded settle-plate module.
-
FY25, the inflection. Nine-plus AstraZeneca units and early BMS and other pharma sales lifted ordinary revenue to A$5.46m. Combined with grant income and R&D tax benefits, the company booked its first net profit (A$1.68m). The quality of earnings was moderate: operating loss was still A$1.17m, so the profit relied on tax benefits and grants.
-
FY26, broadening but lumpier. Placements were flat at 11. But only six were fully recognised as sales; two were partial deposits on evaluations, one was a lease and two were clinical sales via Thermo Fisher. H1 FY26 swung to a A$1.3m loss, and FY26 operating cash flow was -A$2.6m (unaudited). The company's strategy deliberately trades near-term revenue (evaluations and leases) for a broader customer base.
-
Going concern. The auditor flagged a material uncertainty about going concern in FY22 and again at H1 FY26. At 30 June 2026, the 4C showed only 1.08 quarters of funding, with reliance on A$3.4m of expected inflows. These comprise A$1.8m of receivables, a A$0.7m R&D tax incentive and A$0.9m of committed customer inflows.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Ownership | Function |
|---|---|---|---|
Clever Culture Systems Ltd | Australia | Listed parent | R&D, manufacturing management, global sales, corporate |
Clever Culture Systems AG | Switzerland | 100% (since Dec 2021; previously a 50:50 JV with Hettich) | Original APAS commercialisation vehicle |
Revenue stream (AUD K)
| Revenue stream (AUD K) | H1FY25 | H1FY26 |
|---|---|---|
Instrument and accessories sales | 2,401 | 1,963 |
Licence fees | 217 | 302 |
Maintenance services | 135 | 270 |
Consulting services | 70 | 0 |
Total revenue | 2,823 | 2,535 |
Government grants (other income) | 736 | 0 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue, ordinary (AUD Mn, aggregator) | 1.12 | 2.13 | 2.13 | 1.26 | 5.46 |
Total revenue incl. other income (AUD Mn, company) | 2.11 | 2.90 | — | 1.71 | 6.63 |
YoY growth, ordinary revenue (%) | — | 89.5 | 0.2 | -41.1 | 334.8 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue, ordinary (AUD Mn) | 1.12 | 2.13 | 2.13 | 1.26 | 5.46 |
Cost of revenue (AUD Mn) | — | 0.95 | 0.43 | 0.15 | 1.50 |
Gross profit (AUD Mn) | — | 1.18 | 1.71 | 1.11 | 3.96 |
SG&A (AUD Mn) | 4.98 | 5.46 | 4.70 | 4.52 | 4.05 |
R&D expensed (AUD Mn) | 0.22 | 0.24 | 0.30 | 0.67 | 0.07 |
Operating income (AUD Mn) | -6.66 | -7.90 | -7.14 | -4.74 | -1.17 |
Net income (AUD Mn) | -7.26 | -6.64 | -22.52 | -3.74 | 1.68 |
EPS basic (A$ cents) | — | — | — | -0.4 | 0.1 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | — | 55.4 | 80.3 | 88.1 | 72.5 |
Operating margin (%) | -594.6 | -370.9 | -335.2 | -376.2 | -21.4 |
Net margin (%) | -648.2 | -311.7 | -1,057.3 | -296.8 | 30.8 |
Income Statement and Per-Share Data (H1FY25–H1FY26)
| Metric (AUD K) | H1FY25 | H1FY26 |
|---|---|---|
Revenue | 2,823 | 2,535 |
Other income | 945 | 27 |
Cost of sales | 755 | 452 |
Employee benefits expense | 1,322 | 2,115 |
Corporate expenses | 453 | 475 |
Depreciation and amortisation | 155 | 303 |
Profit/(loss) before tax | 621 | -1,684 |
Income tax benefit | 488 | 365 |
Net profit/(loss) | 1,109 | -1,319 |
EPS basic (A$ cents) | 0.07 | -0.07 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (AUD Mn) | — | — | — | 10.77 |
Cash and equivalents (AUD Mn) | — | — | 2.35 | 1.27 |
Inventory (AUD Mn) | — | — | — | 1.43 |
Intangible assets (AUD Mn) | — | — | — | 2.45 |
Borrowings, current (AUD Mn) | — | — | — | 0.18 |
Borrowings, non-current (AUD Mn) | — | — | — | 0.80 |
Lease liabilities (AUD Mn) | — | — | — | 1.24 |
Net debt incl. leases (AUD Mn) | — | — | — | 0.95 |
Total equity (AUD Mn) | — | — | 2.42 | 5.65 |
Working capital (AUD Mn) | — | — | — | 2.91 |
NTA per share (A$ cents) | 4.10 | 0.88 | 0.16 | 0.16 |
Balance Sheet
| Metric (AUD Mn) | 30Jun2025 | 31Dec2025 | 30Jun2026 |
|---|---|---|---|
Cash | 1.27 | 3.10 | 1.69 |
Borrowings (excl. leases) | 0.98 | 0 | 1.50 |
Inventory | 1.43 | 2.16 | — |
Total equity | 5.65 | 8.01 | — |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | — | — | — | — | -2.57 |
Receipts from customers (AUD Mn) | — | — | — | — | 4.90 |
Capex incl. capitalised IP (AUD Mn) | — | — | — | — | 0.48 |
Free cash flow (AUD Mn) | — | — | — | — | -3.05 |
Equity raised / options exercised (AUD Mn) | — | — | — | — | 3.25 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | H1FY26 (31 Dec 2025) | Comment |
|---|---|---|---|
ROE (%) | 41.6 | n/m | Uses average equity A$4.03m; inflated by tax benefits and grants |
ROA (%) | 15.6 | n/m | Uses end assets |
Current ratio (x) | 2.23 | 2.81 | Current assets / current liabilities |
Debt/equity incl. leases (x) | 0.39 | 0.16 | Debt-free ex-leases at Dec 2025; new A$1.6m loan in June 2026 |
Net debt/EBITDA | n/m | n/m | EBITDA negative or not disclosed |
Interest coverage | n/m | n/m | Operating loss |
Asset turnover (x) | 0.51 | n/m | Revenue / total assets |
Revenue by Region
| Region (AUD K) | H1FY25 | H1FY26 | Growth (%) |
|---|---|---|---|
United States | 493 | 789 | 60.0 |
Europe | 1,451 | 1,589 | 9.5 |
Australia | 447 | 143 | -68.0 |
Asia | 432 | 14 | -96.8 |
Total | 2,823 | 2,535 | -10.2 |
Revenue by Region and Revenue by Region (%)
| Metric | FY2025 | H1FY25 | H1FY26 |
|---|---|---|---|
AstraZeneca revenue (AUD K) | — | 1,730 | 865 |
AstraZeneca share of revenue (%) | 80 | 61 | 34 |
Share Price History
| Date | Price (AUD) | Market cap (AUD Mn) | Source |
|---|---|---|---|
Jun 2022 | 0.075 | 24.0 | Biotech Daily |
7 Aug 2024 | 0.021 (intraday 0.027) | — | Motley Fool |
6 Sep 2024 | 0.015 | 24.5 | Biotech Daily |
Nov 2024 | — | 28 | InDaily |
Mid/late 2025 | about 0.027 (52-week range 0.012–0.037) | 56.6–63.5 | Yahoo; TipRanks |
17 Feb 2026 | 0.029 | — | InvestSMART |
30 Apr 2026 | 0.022 | — | InvestSMART |
30 Jul 2026 | 0.017 | about 37 (implied) | InvestSMART |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
EV/Sales (FY25) | about 7.0x | Market cap ≈A$37m, plus A$1.5m debt and A$1.3m leases, less A$1.7m cash (≈A$38m EV), over FY25 revenue A$5.46m |
EV/ARR | about 29x | EV ≈A$38m / ARR A$1.3m |
P/E | n/m | Loss-making (H1 FY26) |
EV/EBITDA | n/m | Negative EBITDA |
P/B | about 4.6x | Market cap ≈A$37m / equity A$8.0m (Dec 2025) |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | No published analyst coverage, rating or price target (Moomoo shows "No Data") |
Dividend history and policy | No dividends ever paid; none proposed |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | A$1.6m principal plus A$0.08m interest due 31 Dec 2026 (unsecured); lease liabilities A$1.31m (Dec 2025); credit card facility A$50k |
Options overhang | About 129m options and performance shares at 31 Dec 2025 (exercise prices mostly A$0.014–0.033), plus 16m lender options from 1 Jul 2026 |
Analyst Conclusions
Management guidance
-
Sales growth expected in FY27, driven by existing customers and the qualified pipeline. No numeric guidance.
-
Expected cash inflows of at least A$3.4m over Q1–Q2 FY27, with up to A$2.6m in Q1 (Q4 FY26 4C).
-
No consensus estimates exist.
Bull case
-
Customer base doubled to eight top-30 pharma companies. Even modest expansion (e.g., 20 extra units at about A$0.5m each) would roughly double FY25 revenue and push ARR toward A$3m.
-
Proven expand template. AstraZeneca went from pilot to eleven units in about two years. Six large pharma customers now share experience through the Expert User Group, which could shorten others' validation cycles.
-
Rising revenue quality. Recurring licence and maintenance revenue is growing at 39–100%, and the full EM offering (settle plus contact) removes a key purchasing objection.
Bear case
-
Funding fragility. Only 1.08 quarters of funding, a A$1.68m bullet repayment in December 2026 and a going-concern emphasis point to probable further dilution at depressed prices.
-
Flat placements despite more logos. Eleven placements in both FY25 and FY26, with FY26 including evaluations, a lease and final Thermo clinical units. Land has not yet produced expand.
-
Competitive and structural friction. Incumbents bundle media and automation, validation is resource-constrained, and the clinical channel has stalled.
Key catalysts and monitorables (next 12 months)
-
Publication of the FY26 audited results, the going-concern wording and any impairment reversal.
-
Collection of the A$3.4m expected inflows in Q1–Q2 FY27 and repayment or refinancing of the December 2026 loan.
-
Conversion of CSL Behring and the unnamed pharma evaluation into purchases; first multi-unit orders from Pfizer, BMS, Novo Nordisk or Boehringer Ingelheim.
-
ARR progression above A$1.3m; validation-services revenue.
-
Status of the Thermo Fisher US distribution agreement (five-year term from Sep 2021).
-
Lead generation from the October–November 2026 conferences.
-
Any capital raise (size, price, dilution).
Analyst verdict
Clever Culture Systems has done what LBT Innovations could not do for a decade: find a market that wants its technology. The pivot from clinical diagnostics to pharmaceutical environmental monitoring has been validated by the customers that matter most. AstraZeneca has bought eleven instruments and its programme won an industry award. Pfizer, BMS, Novo Nordisk, Boehringer Ingelheim, Thermo Fisher Pharma Services and CSL Behring have all placed or evaluated APAS. With settle- and contact-plate modules both validated, the product gap is closed. The question is no longer whether APAS works but how fast regulated manufacturers will deploy it across their networks.
That question is now the entire investment case, and the evidence is incomplete. FY26 delivered breadth rather than depth: placements were flat at eleven, revenue fell in H1, and the business returned to losses after a grant- and tax-assisted FY25 profit. Management's A$50m-plus-A$10m-ARR opportunity within existing customers is plausible in a multi-year frame but unquantified for FY27. Customer-side validation bottlenecks are acknowledged and structural.
The balance sheet is the binding constraint. With A$1.7m cash, about one quarter of funding, a A$1.68m loan due 31 December 2026, an auditor's going-concern emphasis, a large options overhang and about 2.18bn shares on issue, shareholders should expect further capital management. Its terms will depend heavily on Q1–Q2 FY27 receipts and new orders. At about 7x trailing sales and roughly 29x ARR, the market already prices some expansion success.
Verdict: a high-risk, binary micro-cap with genuine product-market validation and a credible but unproven growth path. It is suitable only for speculative capital that can withstand dilution. The decisive monitorables are the first multi-unit orders from a non-AstraZeneca customer, conversion of the two paid evaluations, and how the December 2026 maturity is resolved. Positive outcomes on all three would materially de-risk the story. Failure on any would likely force a dilutive raise at weak prices.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / notes | Independence |
|---|---|---|---|
Rebecca Wilson | Non-Executive Chair | Services from July 2023; Chair from Dec 2023 | Independent |
Brenton (Brent) Barnes | CEO and Managing Director | — | Executive |
Daniel Hill | Non-Executive Director | — | Not disclosed (presumed independent) |
Ian Wisenberg | Non-Executive Director | Appointed Q1 FY25 (Jul–Sep 2024); described as a US pharmaceutical leader; takes part of his fees in shares | Not disclosed (presumed independent) |
Governance Overview
| Element | Detail | Source |
|---|---|---|
CEO short-term incentive | Maximum cash bonus 30% of salary; FY25 bonus A$91,000, taken as 3,545,581 shares at A$0.0258 VWAP | Interim FY26 Note 7 |
CEO long-term incentive | 40m options (exercise A$0.024, vest 10 Jun 2027, expire 10 Dec 2028; fair value A$473k) plus 10m performance shares (vest 10 Dec 2028 subject to a A$0.07 share-price hurdle; fair value A$130k); approved 14 Nov 2024 after the prior LTI was voluntarily relinquished | Interim FY26 Note 8 |
Executive LTI | 40m options on the same terms as the CEO (issued 15 Jan 2025) | Interim FY26 Note 8 |
NED options | Wilson 3.81m; Hill 2.31m; Wisenberg 2.31m (exercise A$0.014; expire 10 Dec 2027) | Interim FY26 Note 8 |
Quarterly director cash payments | A$125,000 in Q4 FY26 (MD salary plus NED fees) | Q4 FY26 4C |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Offering | Relative positioning vs APAS |
|---|---|---|---|
Rapid Micro Biosystems (Nasdaq: RPID) | Pharma EM and QC | Growth Direct automated incubation, imaging and enumeration | — |
bioMérieux | Pharma QC and clinical | Industrial microbiology portfolio including EM data software; clinical lab automation | Global incumbent; former MicroStreak partner |
Copan Diagnostics (with partners) | Clinical (some pharma) | WASPLab with PhenoMATRIX AI plate reading | Leading clinical full-lab automation; competes for clinical AI plate reading |
BD (Becton Dickinson) | Clinical | BD Kiestra lab automation with imaging and AI reading apps | Clinical full-lab automation at large scale |
Merck KGaA / MilliporeSigma | Pharma QC | EM media, monitoring systems, rapid micro methods | Media plus workflow incumbent |
Sartorius | Pharma QC | Microbial QC instruments and consumables | Adjacent |
Charles River Laboratories | Pharma QC | Microbial QC testing and rapid methods | Adjacent (services and rapid methods) |
Thermo Fisher Scientific | Media; also distributor and customer | Culture media; distributes APAS clinically; Thermo Pharma Services is a customer | Partner-competitor dynamic |
Interscience / Synbiosis / Redberry and other plate-counting and imaging vendors | Pharma QC | Colony counters and imaging | Lower-cost, less validated niche |
Manual reading (status quo) | All | Trained microbiologists reading plates | The real competitor; inertia and validation burden |
Peer Comparison FY2025
| Company | Revenue | Growth | Gross margin | R&D intensity | Note |
|---|---|---|---|---|---|
Clever Culture Systems | A$5.46m (FY25) | +335% (FY25) | 72.5% (FY25) | Low expensed; material capitalised | Verified (aggregator plus filings) |
Recent Developments
--



